References
- Ahmad, S. (2017). Kinetic aspects of platinum anticancer agents. Polyhedron, 138, 109–124. doi:10.1016/j.poly.2017.09.016
- Ahmed Ouameur, A., Diamantoglou, S., Sedaghat-Herati, M. R., Nafisi, S., Carpentier, R., & Tajmir-Riahi, H. A. (2006). An overview of drug binding to human serum albumin: Protein folding and unfolding. Cell Biochem. Biophys, 45, 203–213.
- Akdogan, Y., Reichenwallner, J., & Hinderberger, D. (2012). Evidence for water-tuned structural differences in proteins: An approach emphasizing variations in local hydrophilicity. PLoS ONE, 7(9), e45681.
- Apps, M. G., Choi, E. H. Y., & Wheate, N. J. (2015). The state-of-play and future of platinum drugs. Endocrine-Related Cancer, 22(4), R219–R233.
- Aryal, S., Hu, C. M. J., & Zhang, L. (2010). Polymer-cisplatin conjugate nanoparticles for acid-responsive drug delivery. ACS Nano, 26, 251–258.
- Beauchemin, R., N'soukpoé-Kossi, C. N., Thomas, T. J., Thomas, T., Carpentier, R., & Tajmir-Riahi, H. A. (2007). Polyamine analogues bind human serum Albumin. Biomacromolecules, 8(10), 3177–3183.
- Bekale, L., Agudelo, D., & Tajmir-Riahi, H. A. (2015). Effect of polymer molecular weight on chitosan-protein interaction. Colloids and Surfaces B, 125, 309–317.
- Bekale, L., Chanphai, P., Sanyakamdhorn, S., Agudelo, D., & Tajmir-Riahi, H. A. (2014). Microscopic and thermodynamic analysis of PEG-lactoglobulin interaction. RSC Advances, 4(59), 31084–31093.
- Bose, A. (2016). Interaction of tea polyphenols with serum albumins: A fluorescence spectroscopic analysis. Journal of Luminescense., 169, 220–226.
- Brabec, V., Hrabina, O., & Kasparkova, J. (2017). Cytotoxic platinum coordination compounds. DNA binding agents. Coordination Chemistry Reviews, 351, 2–31. doi:10.1016/j.ccr.2017.04.013
- Butler, I. S., & Sadler, P. J. (2013). Targeted delivery of platinum-based anticancer complexes. Current Opinion in Chemical Biology, 17(2), 175–188.
- Byler, D. M., & Susi, H. (1986). Examination of the secondary structure of proteins by deconvoluted FTIR spectra. Biopolymers, 25(3), 469–487.
- Casini, A., & Reedijk, J. (2012). Interactions of anticancer Pt compounds with proteins: An overlooked topic in medicinal inorganic chemistry? Chemical Science, 3(11), 3135–3144.
- Chandra, S., Dietrich, S., Lang, H., & Bahadur, D. (2011). Dendrimer–doxorubicin conjugate for enhanced therapeutic effects for cancer. Journal of Materials Chemistry, 21(15), 5729–5737.
- Chanphai, P., Vesper, A. R., Bekale, L., Bérubé, G., & Tajmir-Riahi, H. A. (2015a). Encapsulation of testosterone and its aliphatic and aromatic dimers by milk beta-lactoglobulin. International Journal of Biological Macromolecules, 76, 153–160.
- Chanphai, P., Vesper, A. R., Bekale, L., Bérubé, G., & Tajmir-Riahi, H. A. (2015b). Transporting testosterone and its dimers by serum proteins. Journal of Photochemistry and Photobiology B, 153, 173–183.
- Chanphai, P., Ouellette, V., Bérubé, G., & Tajmir-Riahi, H. A. (2018). Conjugation of testo and testo-Pt(II) with serum proteins: Loading efficacy and protein conformation. International Journal of Biological Macromolecules, 118, 1112–1119.
- Cohen, G. L., Bauer, W. R., Barton, J. K., & Lippard, S. J. (1979). Binding of cis-and transdichlorodiammineplatinum(II) to DNA: Evidence for unwinding and shortening of the double helix. Science, 203(4384), 1014–1016.
- Collini, M., D'Alfonso, L., & Baldini, G. (2000). New insights on β-lactoglobulin binding sites by 1-anilinonaphthalene-8-sulfonate fluorescence decay. Protein Science, 9(10), 1968–1974.
- Corinti, D., Coletti, C., Re, N., Piccirillo, S., Giampà, M., Crestoni, M. E., & Fornarini, S. (2017). Hydrolysis of cis- and transplatin: Structure and reactivity of the aqua complexes in a solvent free environment. RSC Advances, 7(26), 15877–15884. doi:10.1039/C7RA01182B
- Dousseau, F., Therrien, M., & Pezolet, M. (1989). On the spectral subtraction of water from the FT-IR spectra of aqueous solutions of proteins. Applied Spectroscopy, 43(3), 538–542.
- Elsadek, B., & Kratz, F. (2012). Impact of albumin on drug-delivery-new application on the horizon. Journal of Controlled Release, 157(1), 4–28.
- Essemine, J., Hasni, I., Carpentier, R., Thomas, T. J., & Tajmir-Riahi, H. A. (2011). Binding of biogenic and synthetic polyamines to β-lactoglobulin. International Journal of Biological Macromolecules, 49(2), 201–211. doi:10.1016/j.ijbiomac.2011.04.016
- Ferraro, G., Massai, L., Messori, L., & Merlino, A. (2015). Cisplatin binding to human serum albumin: A structural study. Chemical Communications, 51(46), 9436–9439. doi:10.1039/C5CC01751C
- Ghuman, J., Zunszain, P. A., Petitpas, I., Bhattacharya, A. A., M., Otagiri, & Curry, S. (2005). Structural basis of the drug-binding specificity of human serum albumin. Journal of Molecular Biology, 353(1), 38–52.
- Gokara, M., Kimavath, G. B., Podile, A. R., & Subramanyam, R. (2015). Differential interactions and structural stability of chitosan oligomers with human serum albumin and α-1-glycoprotein. Journal of Biomolecular Structure and Dynamics, 33(1), 196–210.
- Grdadolnik, J. (2003). Saturation effects in FTIR spectroscopy: Intensity of amide I and amide II bands in protein spectra. Acta Chimica Slovenica, 50, 777–788.
- Hasni, I., Bourassa, P., & Tajmir-Riahi, H. A. (2011). Binding of cationic lipids to milk β-lactoglobulin. The Journal of Physical Chemistry B, 115(20), 6683–6690.
- Jameson, G. B., Adams, J. J., & Creamer, L. K. (2002). Flexibility, functionality and hydrophobicity of bovine beta-lactoglobulin. International Dairy Journal, 12(4), 319–329.
- Johnstone, T. C., Suntharalingam, K., & Lippard, S. J. (2016). The next generation of platinum drugs: Targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs. Chemical Reviews, 116(5), 3436–3486.
- Johnstone, T. C., Suntharalingam, K., & Lippard, S. J. (2015). Third row transition metals for the treatment of cancer. Philosophical Transactions of The Royal Society A Mathematical Physical and Engineering Sciences, 373, 20140–20185.
- Kalinowska-Lis, U., Ochocki, J., & Matlawska-Wasowska, K. (2008). Trans geometry in platinum antitumor complexes. Coordination Chemistry Reviews, 252(12–14), 1328–1345.
- Kartalou, M., & Essigmann, J. M. (2001). Recognition of cisplatin adducts by cellular proteins. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis, 478(1–2), 1–21.
- Kasparkova, J., Marini, V., Bursova, V., & Brabec, V. (2008). Biophysical Studies on the Stability of DNA Intrastrand Cross-Links of Transplatin. Biophysical Journal, 95(9), 4361–4371.
- Kratochwil, N. A., Huber, W., Müller, F., Kansy, M., & Gerber, P. R. (2002). Predicting plasma protein binding of drugs: A new approach. Biochemical Pharmacology, 64(9), 1355–1374.
- Kratz, F., & Elsadek, B. (2012). Clinical impact of serum proteins on drug delivery. Journal of Controlled Release, 161(2), 429–445.
- Kratz, F. (2008). Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles. Journal of Controlled Release, 132(3), 171–183.
- Krimm, S., & Bandekar, J. (1986). Vibrational spectroscopy and conformation of peptides, polypeptides, and proteins. Advances in Protein Chemistry, 38, 181–364.
- Lando, D. Y., Chang, C. L., Fridman, A. S., Grigoryan, I. E., Galyuk, E. N., Hsueh, Y. W., & Hu, C. K. (2014). Comparative thermal and thermodynamic study of DNA chemically modified with antitumor drug cisplatin and its inactive analog transplatin. Journal of Inorganic Biochemistry, 137, 85–93.
- Liu, Y. R., Ji, C., Zhang, H. Y., Dou, S. X., Xie, P., Wang, W. C., & &. Wang, P. Y. (2013). Transplatin enhances effect of cisplatin on both single DNA molecules and live tumor cells. Archives of Biochemistry and Biophysics, 536(1), 12–24.
- Mori, H., Hirayama, N., Komeiji, Y., & Mochizuki, Y. (2012). Differences in hydration between cis- and trans-platin: Quantum insights by ab initio fragment molecular orbital-based molecular dynamics (FMO-MD). Computational and Theoretical Chemistry, 986, 30–34.
- Nafisi, S., & Norouzi, Z. (2009). A Comparative study on the interaction of cis- and trans-platin with DNA and RNA. DNA and Cell Biology, 28(9), 469–477.
- Nerusu, A., Reddy, P. S., Ramachary, D. B., & Subramanyam, R. (2017). Unraveling the stability of plasma proteins upon interaction of synthesized androstenedione and its derivatives—A biophysical and computational approach. ACS Omega, 2(10), 6514–6524.
- Painter, L., Harding, M. M., & Beeby, P. J. (1998). Synthesis and interaction with human serum albumin of the first 3,18-disub-stituted derivative of bilirubin. Journal of the Chemical Society, Perkin Transactions, 18, 3041–3044.
- Peleg-Shulman, T., Najajreh, Y., & Gibson, D. (2002). Interactions of cisplatin and transplatin with proteins. Comparison of binding kinetics, binding sites and reactivity of the Pt-protein adducts of cisplatin and transplatin towards biological nucleophiles. Journal of Inorganic Biochemistry, 91(1), 306–311.
- Ross, P. D., & Subramanian, S. (1981). Thermodynamics of protein association reactions: Forces contributing to stability. Biochemistry, 20(11), 3096–3102.
- Song, H., Li, W., Qi, R., Yan, L., Jing, X. N., Zheng, M., & Xiao, H. (2015). Delivering a photosensitive transplatin prodrug to overcome cisplatin drug resistance. Chemical Communications, 51(57), 11493–11495.
- Tian, J., Liu, J., Hu, Z., & Chen, X. (2005). Binding of the scutellarin to albumin using tryptophan fluorescence quenching, CD and FT-IR spectra. American Journal of Immunology, 1, 21–23.
- Wang, D., & Lippard, S. J. (2005). Cellular processing of platinum anticancer drugs. Nature Reviews Drug Discovery, 4(4), 307–320.
- Yang, F., Zhang, Y., & Liang, H. (2014). Interactive association of drugs binding to human serum albumin. International Journal of Molecular Sciences, 15(3), 3580–3595.
- Yeggoni, D. P., Gokara, M., Manidhar, D. M., Rachamallu, A., Nakka, S., Reddy, C. S., & Subramanyam, R. (2014). Binding and molecular dynamics studies of 7-hydroxycoumarin derivatives with human serum albumin and its pharmacological importance. Molecular Pharmaceutics, 11(4), 1117–1131.
- Zhong, W., Wang, Y., Yu, J. S., Liang, Y., Ni, K., & Tu, S. (2004). The interaction of human serum albumin with a novel antidiabetic agent-SU-118. Journal of Pharmaceutical Sciences, 93(4), 1039–1046.